Ensol Biosciences Inc. (XKON:140610)

South Korea flag South Korea · Delayed Price · Currency is KRW
14,200
+200 (1.43%)
At close: Apr 24, 2026
Market Cap192.35B -33.5%
Revenue (ttm)537.46M +208.9%
Net Income-5.40B
EPS-644.00
Shares Out13.55M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,462
Average Volume5,660
Open14,000
Previous Close14,000
Day's Range13,900 - 14,490
52-Week Range10,350 - 38,800
Beta0.82
RSI51.88
Earnings Daten/a

About Ensol Biosciences

Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis. It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for th... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 140610
Full Company Profile